Inhibition of methadone and buprenorphine N-dealkylations by three HIV- 1 protease inhibitors

Drug Metabolism and Disposition

Volumn 26, Issue 3, 1998, Pages 257-260

  Iribarne, Christelle ^b   Berthou, François ^a   Carlhant, Dominique ^b   Dreano, Yvonne ^b   Picart, Daniel ^b   Lohezic, Françoise ^b   Riche, Christian ^b  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BUPRENORPHINE; CYTOCHROME P450; INDINAVIR; METHADONE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; COMPETITIVE INHIBITION; DEALKYLATION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEINASE INHIBITION; VIRUS INHIBITION;

ALKYLATION; BUPRENORPHINE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; KINETICS; METHADONE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, N-DEMETHYLATING; RITONAVIR; SAQUINAVIR;

EID: 0031942863     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Balani SK, Woolf EJ, Hoagland VL, Sturgill MG, Deutsch PJ, Yeh KC and Lin JH (1996) Disposition of indinavir, a potent HIV-1 protesse inhibitor, after an oral dose in humans. Drug Metab Dispos 24:1389-1394.
2. Barry M, Gibbons S, Back D and Mulcahy F (1997) Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations. Clin Pharmacokinet 32:194-209.
3. Berthou F, Flinois JP, Ratanasavanh D, Beaune P, Riché C and Guillouzo A (1991) Evidence for the involvement of several cytochrome P450s in the first-step of caffeine metabolism by human liver microsomes. Drug Metab Dispos 19:561-567.
4. Berthou F, Dréano Y, Belloc C, Kangas L, Gautier JC and Beaune P (1994) Involvement of cytochrome P450 3A4 enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol 47:1883-1895.
5. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
6. Chiba M, Hensleigh M, Nishime JA, Balani SK and Lin JH (1996) Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent HIV protease inhibitor. Drug Metab Dispos 24:307-314.
7. Chiba M, Hensleigh M and Lin JH (1997) Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor in rat and human microsomes: Major role of CYP3A. Biochem Pharmacol 53:1187-1195.
8. David JC (1995) Biochimie Enzymatique (Lavoisier, ed) pp. 59-66, Paris.
9. Deeks SG, Smith M, Holodniy M and Kahn JO (1997) HIV protease inhibitors. JAMA 277: 145-153.
10. Dole VP and Nyswander M (1965) A medical treatment for diacetylmorphine (heroine) addiction. JAMA 193:646-650.
11. Eagling VA, Back DJ and Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
12. Fitzsimmons ME and Collins JM (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small intestinal cytochrome P450 3A4: Potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266.
13. Guengerich FP (1996) In vitro techniques for studying drug metabolism. J Pharmacokin Biopharm 24:521-533.
14. Iribarne C, Berthou F, Baird S, Dréano Y, Picart D, Bail JP, Beaune P and Ménez JF (1996) Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 9:365-373.
15. Iribame C, Picart D, Dréano Y, Bail JP and Berthou F (1997a) Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver micromes. Life Sci 60:1953-1964.
16. Iribarne C, Dréano Y, Bardou LG, Ménez JF and Berthou F (1997b) Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 117:13-23.
17. Jacolot F, Simon I, Dréano Y, Beaune PH, Riché C and Berthou F (1991) Identification of the cytochrome P450 IIIA family as the enzyme involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41:1911-1919.
18. Kumar GN, Rodrigues AD, Buko AM and Denissen JF (1996) Cytochrome P450 medialed metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423-431.
19. Lea P and Faulds D (1996) Ritonavir. Drugs 52:541-546.
20. Li AP, Kaminski DL and Rasmussen A (1995) Substrates of hepatic cytochrome P450 3A4. Toxicology 104:1-8.
21. Mello NK and Mendelson JH (1980) Buprenorphine suppresses heroin use by heroin addicts. Science 207:657-659.
22. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tjia JF, Gibbons SE, Breckenridge AM and Back DJ (1997) Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11:F29-F33.
23. Noble S and Faulds D (1996) Saquinavir: A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52:93-112.
24. Ring BJ, Binkley SN, Roskos L and Wrighton SA (1995) Effect of fluoxetine, norfluoxetine, sertraline and desmethylsertraline on human CYP3A catalyzed 1′-hydroxy-midazolam formation in vitro. J Pharmacol Exp Ther 275:1131-1135.
25. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
26. Verebely K, Volavka J. Mulé S and Resnick R (1975) Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 18:180-190.
27. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS and Shader RI (1994) Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268:1278-1283.